AtaiBeckley Inc. (NASDAQ:ATAI) is one of the The best budget stocks to buy for under $5.. On March 3, AtaiBeckley announced a successful end-of-Phase 2 meeting with the FDA regarding BPL-003, a proprietary intranasal formulation of mebufotenine benzoate for treatment-resistant depression/TRD. The FDA indicated its support for the proposed Phase 3 program, providing constructive comments on the design and requirements of the safety database for this chronic indication.
This milestone follows Breakthrough Therapy designation granted in late 2025, and the company remains on track to initiate the Phase 3 program in the second quarter of 2026. The Phase 3 program consists of two parallel pivotal studies, ReConnection 1 and ReConnection 2, followed by a 52-week open-label extension to evaluate long-term safety and individualized retreatment. ReConnection 1 will evaluate single doses of 8 mg and 4 mg versus placebo to characterize the dose-response relationship, while ReConnection 2 will investigate a two-dose induction model on day 1 and day 15.
Designed to fit into existing interventional psychiatry workflows, BPL-003 aims to offer a rapid and long-lasting treatment option with a clinical experience of approximately two hours. AtaiBeckley Inc. (NASDAQ:ATAI) believes this model addresses important barriers for patients and providers by requiring only a few treatments per year.
AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company that researches, develops and commercializes mental health treatments in the US, Germany and Canada.
While we recognize ATAI’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: The 40 most popular stocks among hedge funds heading into 2026 and the 12 most promising microcap stocks according to analysts.
Disclosure: None. Follow Insider Monkey on Google News.